Products
Turoctocog alfa pegol was approved in the US, EU, and many countries in 2019 as a powder and solvent for solution for injection (Esperoct).
Structure and properties
Turoctocog alfa pegol is a recombinant and modified human factor VIII (rFVIII) produced by biotechnological methods. A polyethylene glycol (PEG) with a molecular mass of 40 kDa is bound to the protein.
Effects
Turoctocog alfa pegol (ATC B02BD02) replaces the missing or insufficient blood clotting factor VIII and enables blood clotting. Pegylation increases the half-life by a factor of 1.6.
Indications
For the prevention and treatment of patients aged 12 years and older with hemophilia A (congenital factor VIII deficiency).
Dosage
According to the SmPC. The drug is administered as an intravenous injection.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Interactions
Interactions with other drugs are not known to date.
Adverse effects
The most common possible adverse effects include injection site reactions and skin rashes.